Paul Kenny, PhD, Appointed Chair of the Department of Neuroscience at the Icahn School of Medicine at Mount Sinai
Renowned neurobiologist Paul Kenny, PhD, has been named Chairman of the Department of Neuroscience at the Icahn School of Medicine at Mount Sinai.
Dr. Kenny is an internationally recognized expert in the study of the neurobiology of obesity and drug addiction. His multidisciplinary studies use behavioral paradigms, physiological and circuit analyses, and molecular characterization of neurobehavioral disorders to uncover new signaling cascades that may play a role in these disorders.
“Dr. Kenny’s outstanding academic credentials coupled with his innovative approach to discovery and excellent administrative skills makes him an ideal fit for his new leadership role in the Department of Neuroscience,” says Dennis S. Charney, MD, Anne and Joel Ehrenkranz Dean of the Icahn School of Medicine at Mount Sinai, and President for Academic Affairs, Mount Sinai Health System. “We have every confidence that Paul will foster the advancement of cutting-edge and translational science that has made the Department of Neuroscience at Mount Sinai among the most outstanding in the world.”
Prior to taking on this new role, Dr. Kenny served as Chairman of the Department of Pharmacology and System Therapeutics. He was recruited to Mount Sinai from The Scripps Research Institute in Florida in 2014, and since then has continued to build on his compelling scientific vision. Dr. Kenny will continue to serve as Director of the Mount Sinai Experimental Therapeutics Institute.
Dr. Kenny completed his PhD in Neuroscience at King's College London. After postdoctoral training at The Scripps Research Institute in La Jolla, California, Dr. Kenny became Assistant Professor of Molecular Therapeutics at the Institute’s campus in Florida. Dr. Kenny has also served as Director of the Medications Development Program in Substance-Related Disorders at Scripps.
He has won numerous awards, including several Young Investigator Awards from groups that include the Society for Neuroscience, the National Alliance for Research on Schizophrenia and Depression, and the Society for Research on Nicotine and Tobacco. He is an editor of The Journal of Neuroscience, and an editorial board member of several additional journals. Dr. Kenny is also a member of the National Advisory Council on Alcohol Abuse and Alcoholism (NIAAA).
About the Mount Sinai Health System
Mount Sinai Health System is one of the nation’s leading integrated academic health systems and one of the largest in the New York metropolitan area. Its comprehensive system includes seven hospitals, more than 400 outpatient practices, over 600 research and clinical laboratories, the Icahn School of Medicine at Mount Sinai, the Graduate School of Biomedical Sciences, and the Mount Sinai Phillips School of Nursing. Together, the Health System comprises approximately 48,000 employees, more than 9,000 physicians, and 8,600 nurses.
As a leading learning health system, Mount Sinai combines clinical expertise with scientific discovery to improve patient care while training the next generation of health care and biomedical leaders. The Health System provides care across every stage of life, from prenatal care through geriatrics, while advancing personalized medicine through artificial intelligence, data science, and biomedical research.
Mount Sinai is consistently recognized among the nation’s leading academic health systems for patient care, research, and education. The Mount Sinai Hospital is ranked No. 1 in New York by Newsweek and No. 5 on the magazine’s World’s Best Hospitals list. The Icahn School of Medicine at Mount Sinai ranks No. 11 among U.S. medical schools and No. 1 among freestanding medical schools for National Institutes of Health funding, reflecting the strength of its scientific enterprise and leadership in biomedical research.
